NKGen Biotech, HekaBio Partner to Develop NK Cell Therapy in Japan
NKGen Biotech, HekaBio Partner to Develop NK Cell Therapy in Japan

NKGen Biotech, HekaBio Partner to Develop NK Cell Therapy in Japan

News summary

NKGen Biotech has entered a strategic collaboration with Tokyo-based HekaBio K.K. to develop, manufacture, and commercialize its autologous NK cell therapy, troculeucel, targeting neurodegenerative diseases such as Alzheimer's and Parkinson's in Japan. HekaBio will lead clinical trials and regulatory activities, leveraging Japan's expedited Regenerative Medicine guidelines to potentially begin patient dosing within the next year. The partnership aims to address significant health challenges posed by Japan's aging population and capitalize on faster market access provided by local regulations. Concurrently, NKGen secured $2 million in funding through a stock purchase agreement with HekaBio, which will support regulatory compliance efforts and the company's goal to uplist from the OTC Expert Market to higher exchanges like OTCQB, Nasdaq, or NYSE American. This funding also helps NKGen recover from challenges related to the bankruptcy of its former parent company, NKMax Co., Ltd., and to continue advancing its clinical trials and commercialization strategy in Japan. The collaboration underscores NKGen's commitment to bringing innovative cell therapies to markets with high unmet medical needs.

Story Coverage
Bias Distribution
100% Left
Information Sources
daae85f0-2883-42fc-b085-888140adf30d
Left 100%
Coverage Details
Total News Sources
1
Left
1
Center
0
Right
0
Unrated
0
Last Updated
1 day ago
Bias Distribution
100% Left
Related News
Daily Index

Negative

22Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News